Recombinant Human Erythropoietin and Hemoglobin Concentration at Operation and during the Postoperative Period: Reduced Need for Blood Transfusions in Patients Undergoing Colorectal Surgery—Prospective Double-blind Placebo-controlled Study

1999 ◽  
Vol 23 (1) ◽  
pp. 30-35 ◽  
Author(s):  
Niels Qvist ◽  
Steen Boesby ◽  
Birgit Wolff ◽  
Carsten P. Hansen
Keyword(s):  
Colorectal Surgery ◽  
Postoperative Period ◽  
Recombinant Human Erythropoietin ◽  
Hemoglobin Concentration ◽  
Controlled Study ◽  
Blood Transfusions ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Human Erythropoietin

Recombinant Human Erythropoietin in the Treatment of the Anemia of Prematurity: Results of a Double-Blind, Placebo-Controlled Study

PEDIATRICS ◽  
1994 ◽  
Vol 93 (6) ◽  
pp. 918-923
Author(s):  
Michael P. Meyer ◽  
F. Mary Hann ◽  
Alan A. Sive ◽  
Geoffery Moller ◽  
Atties F. Malan ◽  
...  
Keyword(s):  
Preterm Infants ◽  
Recombinant Human Erythropoietin ◽  
Reticulocyte Count ◽  
Sudden Infant Death ◽  
Controlled Study ◽  
Sudden Infant ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Human Erythropoietin ◽  
Anemia Of Prematurity

Objective. To assess the efficacy of recombinant human erythropoietin (rHuEpo) in the treatment of the anemia of prematurity. Methodology. A double-blind, placebo-controlled study was conducted on 80 preterm infants (≤32 weeks; postnatal age, 2 to 8 weeks; central hematocrit ≤35%). Patients were randomly assigned to receive subcutaneous rHuEpo (Eprex, 600 U/kg per week) or an equivalent volume of placebo, for up to 6 weeks. All patients received supplements of vitamin E (25 IU) and iron (3 mg/kg per day). The iron supplement was increased if declining serum ferritin measurements were noted. Results. Treatment and placebo groups did not differ significantly with respect to mean gestational age, birth weight hematocrit, or reticulocyte count at study entry. Fewer transfusions were administered to those receiving erythropoietin (7 compared with 21; P = .002). Compared with the placebo group, the infants receiving rHuEpo had a higher mean hematocrit (32.3 ± 4% vs 29.3 ± 6.2%; P = .014) and absolute reticulocyte count (223 ± 73 vs 124.9 ± 73 x 109/L; P < .001) at the end of the study. The mean neutrophil count was not significantly reduced at study exit (P = .8), nor at any other period during the trial in the rHuEpo group. Intercurrent events (mostly infections) were not increased in the treatment group, although there was one case of sudden infant death syndrome at age 4 months. Conclusions. Using a dose of rHuEpo of 600 U/kg per week, this study has shown a clear reduction in the requirement for blood transfusion in preterm infants.

scholarly journals Randomized, double-blind, placebo-controlled study of the efficacy of four probiotics to modify the risk for postoperative complications in colorectal surgery

Critical Care ◽  
2015 ◽  
Vol 19 (Suppl 1) ◽  
pp. P390
Author(s):  
K Kotzampassi ◽  
G Stavrou ◽  
G Damoraki ◽  
M Georgitsi ◽  
G Basdanis ◽  
...  
Keyword(s):  
Postoperative Complications ◽  
Colorectal Surgery ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo

Efficacy of recombinant human erythropoietin in the critically ill patient: A randomized, double-blind, placebo-controlled trial

1999 ◽  
Vol 27 (11) ◽  
pp. 2346-2350 ◽  
Author(s):  
Howard L. Corwin ◽  
Andrew Gettinger ◽  
Robert M. Rodriguez ◽  
Ronald G. Pearl ◽  
K. Dean Gubler ◽  
...  
Keyword(s):  
Critically Ill ◽  
Recombinant Human Erythropoietin ◽  
Controlled Trial ◽  
Critically Ill Patient ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Human Erythropoietin

scholarly journals Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers

Blood ◽  
1990 ◽  
Vol 76 (9) ◽  
pp. 1718-1722 ◽  
Author(s):  
FG McMahon ◽  
R Vargas ◽  
M Ryan ◽  
AK Jain ◽  
RI Abels ◽  
...  
Keyword(s):  
Recombinant Human Erythropoietin ◽  
Controlled Study ◽  
Normal Male ◽  
Double Blind ◽  
Subcutaneous Injections ◽  
Human Erythropoietin ◽  
Multiple Doses ◽  
Adverse Experiences ◽  
Clinically Significant ◽  
Male Subjects

A double-blind, placebo-controlled study of the pharmacokinetics and safety of multiple doses of recombinant human erythropoietin [rHuEPO 150 or 300 U/kg either by intravenous (IV) bolus or subcutaneously (SC)] in normal male subjects demonstrated that rHuEPO had a dose- related effect on the hematocrit independent of the route of administration and that multiple doses of rHuEPO had no direct pressor effects. When rHuEPO was injected IV, a monoexponential decrease in serum EPO level was evident for 18 to 24 hours postdose. Absorption of SC injected rHuEPO occurred more slowly, with relatively low serum EPO levels being maintained for 48 hours. All rHuEPO antibody titer determinations were negative. With the exception of significant increases in hemoglobin and hematocrit, no clinically significant changes occurred. No hypertensive, convulsive, or thrombotic events were observed. Of the adverse experiences observed in 10 subjects, none was considered clinically significant, and none of the subjects dropped out because of adverse experiences.

A Four-Probiotics Regimen Reduces Postoperative Complications After Colorectal Surgery: A Randomized, Double-Blind, Placebo-Controlled Study

2015 ◽  
Vol 39 (11) ◽  
pp. 2776-2783 ◽  
Author(s):  
Katerina Kotzampassi ◽  
George Stavrou ◽  
Georgia Damoraki ◽  
Marianna Georgitsi ◽  
George Basdanis ◽  
...  
Keyword(s):  
Postoperative Complications ◽  
Colorectal Surgery ◽  
Controlled Study ◽  
Double Blind ◽  
Double Blind Placebo
Sign in / Sign up

Export Citation Format

Share Document